OPKO Health's (OPK) Buy Rating Reiterated at HC Wainwright

OPKO Health (NASDAQ:OPK - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $3.00 price target on the biotechnology company's stock. HC Wainwright's price objective indicates a potential upside of 112.01% from the stock's previous close. HC Wainwright also issued estimates for OPKO Health's Q3 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.29) EPS.

A number of other brokerages also recently issued reports on OPK. StockNews.com raised shares of OPKO Health from a "sell" rating to a "hold" rating in a research report on Monday, March 3rd. Barrington Research reaffirmed an "outperform" rating and set a $2.25 price target on shares of OPKO Health in a research report on Wednesday, March 12th.

OPKO Health Stock Up 4.0 %

OPKO Health stock traded up $0.06 during midday trading on Monday, hitting $1.42. 2,666,302 shares of the company's stock were exchanged, compared to its average volume of 3,953,693. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The company has a market cap of $950.24 million, a PE ratio of -7.45 and a beta of 1.78. The firm has a 50-day moving average of $1.69 and a two-hundred day moving average of $1.58. OPKO Health has a 12 month low of $1.15 and a 12 month high of $2.04.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. The company had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. As a group, analysts expect that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Phillip Md Et Al Frost purchased 125,000 shares of the stock in a transaction on Thursday, April 10th. The stock was bought at an average price of $1.36 per share, with a total value of $170,000.00. Following the transaction, the chief executive officer now owns 214,001,448 shares in the company, valued at $291,041,969.28. The trade was a 0.06 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders purchased 1,464,971 shares of company stock worth $2,268,692 in the last three months. Corporate insiders own 49.69% of the company's stock.

Hedge Funds Weigh In On OPKO Health

A number of institutional investors have recently bought and sold shares of OPK. FMR LLC raised its holdings in shares of OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 11,089 shares during the last quarter. BNP Paribas Financial Markets grew its position in OPKO Health by 736.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company's stock worth $368,000 after purchasing an additional 217,450 shares during the period. Verition Fund Management LLC purchased a new position in shares of OPKO Health during the 3rd quarter valued at about $201,000. Point72 DIFC Ltd acquired a new position in shares of OPKO Health in the 3rd quarter valued at about $71,000. Finally, XTX Topco Ltd boosted its stake in shares of OPKO Health by 166.5% in the third quarter. XTX Topco Ltd now owns 108,652 shares of the biotechnology company's stock worth $162,000 after buying an additional 67,883 shares during the last quarter. 64.63% of the stock is owned by hedge funds and other institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.